Abstract 19736: Rivaroxaban and Apixaban for Treatment of Venous Thrombosis of Atypical Location

Background: Effectiveness and safety of novel oral anticoagulants (NOACs) for treatment of venous thrombosis of “atypical” location such as: portal, mesenteric, hepatic, splenic, gonadal, renal, and cerebral veins is essentially unexplored. Methods: Consecutive patients treated with rivaroxaban or apixaban for venous thromboembolism (VTE), enrolled into Mayo Thrombophilia Registry between March 1, 2013, and May 30, 2016, were followed prospectively. Results: During study period there were 604 VTE patients [544 with typical (leg deep vein thrombosis or pulmonary embolism) and 60 with atypical location], and 286 (79 treated with apixaban) had at least 3 months of follow up. Of these, 24 (8%) had atypical VTE: portal (9), ovarian (6), mesenteric (6), renal (3), splenic (1), and cerebral (1); one patient had portal and mesenteric, another ovarian and renal thrombosis. Patients with atypical VTE were younger compared to typical VTE patients; two-third of them had malignancy (see Table). Two patients in atypica...